Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 1
2006 5
2007 5
2008 6
2009 5
2010 15
2011 13
2012 4
2013 2
2014 5
2015 5
2016 7
2017 11
2018 12
2019 21
2020 18
2021 7
2022 6
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages.
Feurstein S, Trottier AM, Estrada-Merly N, Pozsgai M, McNeely K, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, Nakamura R, Kim S, Hu Z, Sobecks R, Spellman S, Saber W, Godley LA. Feurstein S, et al. Among authors: sobecks r. Blood. 2022 Dec 15;140(24):2533-2548. doi: 10.1182/blood.2022015790. Blood. 2022. PMID: 35969835 Free PMC article.
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.
Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A, D'Aveni M, Aarnink A, Rubio MT, Feugier P, Ferraro F, Carraway HE, Sobecks R, Hamilton BK, Majhail NS, Visconte V, Maciejewski JP. Pagliuca S, et al. Among authors: sobecks r. Nat Commun. 2023 May 31;14(1):3153. doi: 10.1038/s41467-023-38113-4. Nat Commun. 2023. PMID: 37258544 Free PMC article.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Bolaños-Meade J, et al. Among authors: sobecks r. Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7. Lancet Haematol. 2019. PMID: 30824040 Free PMC article. Clinical Trial.
Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention.
Hamilton BK, Rybicki LA, Li H, Lucas T, Corrigan D, Kalaycio M, Sobecks R, Hanna R, Rotz SJ, Dean RM, Gerds AT, Jagadeesh D, Brunstein C, Sauter CS, Copelan EA, Majhail NS. Hamilton BK, et al. Among authors: sobecks r. Blood Adv. 2023 Aug 22;7(16):4505-4513. doi: 10.1182/bloodadvances.2023010310. Blood Adv. 2023. PMID: 37352262 Free PMC article. Clinical Trial.
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
Metheny LL, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, Ciarrone L, Kopp S, Convents RD, Majhail N, Caimi PF, Otegbeye F, Cooper BW, Gallogly M, Malek E, Tomlinson B, Gerds AT, Hamilton B, Giralt S, Perales MA, de Lima M. Metheny LL, et al. Among authors: sobecks r. Blood Adv. 2024 Mar 26;8(6):1384-1391. doi: 10.1182/bloodadvances.2023011514. Blood Adv. 2024. PMID: 38170741 Free PMC article.
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R. Mei M, et al. Among authors: sobecks rm. Haematologica. 2023 Jan 1;108(1):150-160. doi: 10.3324/haematol.2021.280203. Haematologica. 2023. PMID: 35443559 Free PMC article.
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring.
Gaffney KJ, Urban TA, Lucena M, Anwer F, Dean RM, Gerds AT, Hamilton BK, Jagadeesh D, Kalaycio ME, Khouri J, Pohlman B, Sobecks R, Winter A, Rybicki L, Majhail NS, Hill BT. Gaffney KJ, et al. Among authors: sobecks r. J Oncol Pharm Pract. 2022 Jun 7:10781552221104422. doi: 10.1177/10781552221104422. Online ahead of print. J Oncol Pharm Pract. 2022. PMID: 35673764
Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant.
Hegde PS, Rybicki L, Serafino S, Bernhard L, Corrigan D, Anwer F, Kalaycio M, Sobecks RM, Jagadeesh D, Hill BT, Dean RM, Khouri J, Winter AM, Pohlman B, Majhail NS, Hamilton BK. Hegde PS, et al. Among authors: sobecks rm. Bone Marrow Transplant. 2022 Jun;57(6):1031-1033. doi: 10.1038/s41409-022-01677-8. Epub 2022 Apr 15. Bone Marrow Transplant. 2022. PMID: 35428866 No abstract available.
Survival following allogeneic transplant in patients with myelofibrosis.
Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Gowin K, et al. Among authors: sobecks r. Blood Adv. 2020 May 12;4(9):1965-1973. doi: 10.1182/bloodadvances.2019001084. Blood Adv. 2020. PMID: 32384540 Free PMC article.
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.
Mian A, Wei W, Hamilton BK, Winter AM, Khouri J, Pohlman B, Gerds AT, Jagadeesh D, Anwer F, Kalaycio M, Dean RM, Sobecks R, Caimi PF, Hill BT, Majhail NS. Mian A, et al. Among authors: sobecks r. Bone Marrow Transplant. 2023 May;58(5):590-593. doi: 10.1038/s41409-023-01934-4. Epub 2023 Feb 11. Bone Marrow Transplant. 2023. PMID: 36774431 No abstract available.
132 results